Radiation Therapy for Anal Cancer

 

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells. It can be given internally or externally.

  • External beam radiation therapy (EBRT) - EBRT is the most common type of radiation treatment for anal cancer. Radiation from a high-energy x-ray machine (linear accelerator) outside the body is focused on the cancer cells. The radiation may focus on some of the pelvis to treat lymph nodes in the groin because anal cancer often spreads to these lymph nodes. EBRT can harm both the cancer cells and nearby healthy tissue. Most people are treated with EBRT for a few minutes 5 days a week for 5 or 6 weeks as an outpatient.
  • Internal radiation therapy (brachytherapy or interstitial radiation therapy) - Small pellets (or “seeds”) that contain radioactive materials are placed in your body in or near the tumor. The radioactive pellets release their radiation slowly over time. Brachytherapy lets the doctor use a higher dose of radiation than EBRT. It is sometimes used for people with anal cancer, especially if they are too sick or weak to have curative surgery. This type of treatment involves a one-time procedure.

Sometimes, internal and external radiation therapies are used together.

If you have been infected with the human immunodeficiency virus (HIV, the virus that causes AIDS), you are more likely to have side effects during and after radiation treatment. The radiation can weaken your immune system, which is already vulnerable because of the HIV. These side effects could make it harder for you to go through and complete treatment. For this reason, your doctor may recommend lower doses of radiation if you have HIV.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on March 24, 2008 .
Latest Cancer News
Zevalin® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant

September 5, 2008 — Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.

Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes

September 5, 2008 — Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.

US FDA lists drugs under safety probes

September 5, 2008 — WASHINGTON (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's antidepressant Cymbalta, Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri and more than a dozen other medicines.

Select news items provided by Reuters Health